levofloxacin, and tetracycline was used for the remaining five days. Sitafloxacin has superior activity against H. pyloriwith gyrA mutations, and two studies have shown better eradication rates as third-line therapy, compared to levofloxacin-based treatment (75%; 78.2%, respectively). The authors conclude that, in the event of treatment failure, the clinician should always check for poor patient compliance due to adverse reactions to the medications, or patient difficulties complying with the therapy regimen. Due to high resistance rates, an effort should be made before starting therapy to confirm if the patient has had several courses of antibiotics for other infections in the past. Acknowledgements QUICK REFERENCE GUIDE AUTHORS Prof Cliodna McNulty, Head of Primary Care Unit and Honorary Visiting Professor, Public Health England and Cardiff University Dr Philippa Moore, Consultant Microbiologist, Gloucestershire Hospitals NHS Foundation Trust Dr Teh Li Chin, Consultant Microbiologist, North Bristol NHS Trust
levofloxacin, and tetracycline was used for the remaining five days. Sitafloxacin has superior activity against H. pyloriwith gyrA mutations, and two studies have shown better eradication rates as third-line therapy, compared to levofloxacin-based treatment (75%; 78.2%, respectively). The authors conclude that, in the event of treatment failure, the clinician should always check for poor patient compliance due to adverse reactions to the medications, or patient difficulties complying with the therapy regimen. Due to high resistance rates, an effort should be made before starting therapy to confirm if the patient has had several courses of antibiotics for other infections in the past. Acknowledgements QUICK REFERENCE GUIDE AUTHORS Prof Cliodna McNulty, Head of Primary Care Unit and Honorary Visiting Professor, Public Health England and Cardiff University Dr Philippa Moore, Consultant Microbiologist, Gloucestershire Hospitals NHS Foundation Trust Dr Teh Li Chin, Consultant Microbiologist, North Bristol NHS Trust
hellicobacter_pylori_quick_reference_guide.docx